Report on ivermectin + carrageenan prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin. The effect is likely to be primarily due to ivermectin - the creator of the protocol has later reported that carrageenan is not necessary . Preliminary results from: .
Vallejos et al., 12/20/2020, retrospective, Argentina, South America, preprint, 1 author, dosage 12mg weekly.
risk of COVID-19 case, 73.6% lower, RR 0.26, p < 0.001, treatment 11 of 389 (2.8%), control 52 of 486 (10.7%).
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of